ALUMIS INC

Company Overview

Alumis is a clinical‑stage biopharmaceutical company focused on replacing broad immunosuppression with targeted TYK2 inhibitors and precision‑guided discovery. Its lead oral allosteric TYK2 candidate ESK‑001 is in a global Phase 3 (ONWARD) program for moderate‑to‑severe plaque psoriasis and a Phase 2b trial for systemic lupus erythematosus, while A‑005 is a CNS‑penetrant TYK2 candidate in Phase 1 targeting MS and neuroinflammation. The company runs a vertically light R&D model (in‑house discovery, clinical and regulatory strategy) and outsources manufacturing to CMOs (notably suppliers in India and Taiwan), has ~170 employees, is not yet commercial, and is highly milestone‑driven with material dependency on external partners and regulatory outcomes. A February 2025 merger with Acelyrin and recent collaboration/license revenue (e.g., Kaken) materially affect scale, cash position and near‑term strategic priorities.

Executive Compensation Practices

Compensation at Alumis is likely heavily equity‑based and milestone‑oriented: management disclosed $19.5M of stock‑based compensation in 2024 and about $54.4M of unrecognized stock awards (~2.5 year vesting), reflecting industry norms for pre‑commercial biotech to conserve cash while aligning pay to long‑dated value creation. Given the company’s clinical and regulatory inflection points (Phase 3 ONWARD topline, SLE readouts, partnership milestones) incentive plans will likely tie payouts to clinical, regulatory and partnering milestones, plus retention/transaction awards related to the Acelyrin merger. Cash pay is constrained by rapid R&D spend and intermittent financings, so expect a mix of options/RSUs, performance‑based equity, and change‑of‑control or retention severance provisions that can accelerate vesting and affect dilution. Valuation and accounting judgments (stock‑comp valuation, fair value of common stock/derivatives) materially influence reported compensation expense and can drive timing of grant practices.

Insider Trading Considerations

Trading patterns at Alumis are likely concentrated around clinical readouts, regulatory filings, partnership/license announcements (e.g., Kaken, FronThera milestones) and merger milestones (Acelyrin close), which are the principal value drivers and typical catalysts for insider buys/sells. Key signals to monitor: insider purchases ahead of or after positive trial/regulatory outcomes (confidence signal), and insider sales following vesting or to meet diversification/liquidity needs—sales can also precede dilutive financings and be interpreted as a liquidity signal. Regulatory constraints (Section 16 reporting, 10b5‑1 plans, Rule 10b‑5 prohibition on trading on material nonpublic information) and customary lock‑ups around IPOs/mergers will shape timing; additionally, transaction‑related accelerated vesting, severance or bargain‑purchase accounting recognized at close can trigger sizable reported insider transactions. Finally, supply‑chain or CMO disruptions and safety events (SAEs in OLEs) are operational risk events that can produce abrupt insider activity and should be watched closely.